Romosozumab is not only a promising agent for the management of osteoporosis, but is also exerts positive effects on bone involvement in multiple myeloma, where increased levels of sclerostin may contribute to the development of lytic lesion. This evidence concerns the gene SOST and plasma cell myeloma.